Ditsetel - a drug intended for the treatment of functional disorders of the gastrointestinal tract.
Release form and composition
Ditsetel is produced in the form of round orange biconvex tablets, film-coated, on one side of which there is an engraving “50”, and on the other side there is a symbol of a square under the letter “S” in blisters of 20 pieces each.
The composition of one tablet includes 50 mg of pinaveria bromide and such excipients as:
- 17 mg of pregelatinized starch;
- 3 mg talc;
- 1.5 mg of magnesium stearate;
- 1 mg of colloidal silicon dioxide;
- 18.5 mg lactose monohydrate;
- 79.35 mg of microcrystalline cellulose.
The film coating of the tablets consists of 0.818 mg of sodium lauryl sulfate, 8.176 mg of butyl methacrylate copolymer, 6.473 mg of talc, 0.341 mg of dry semisperse 3203, and 1.192 mg of stearic acid.
They also produce round orange biconvex film-coated Ditsetel tablets in blister packs of 20 pcs. On one side of the tablets there is an engraving “100”, and on the other - a square symbol under the letter “S”.
One tablet contains 100 mg of pinaveria bromide and excipients - 36.3 mg of lactose monohydrate, 2 mg of colloidal silicon dioxide, 3 mg of magnesium stearate, 34 mg of pregelatinized starch, 158.7 mg of microcrystalline cellulose and 6 mg of talc.
The composition of the film envelope includes 0.682 mg of dry septispers 3203, 16.352 mg of butyl methacrylate copolymer, 1.636 mg of sodium lauryl sulfate, 2.384 mg of stearic acid and 12.946 mg of talc.
Indications for use
Ditsetel use in cases:
- Symptomatic treatment of intestinal contents transit disorders, pain and discomfort due to functional disorders of the intestine;
- Preparing the patient for X-ray examination of the gastrointestinal tract using barium sulfate;
- Symptomatic treatment of pain associated with functional disorders of the biliary tract.
Ditsetel application is contraindicated in children under 18 years of age, in case of hypersensitivity to the active and auxiliary components of the product, as well as in the following cases:
- Glucose-galactose malabsorption;
- Intolerance to galactose;
- Lactase deficiency.
During pregnancy and during the breastfeeding period, the use of the drug is permissible only in cases where the expected effect of the therapy significantly exceeds the possible risk to the developing fetus or infant.
Dosing and Administration
Tablets are taken orally during the meal, drinking water. Ditsetel dosage is 50 mg three times a day, or 100 mg twice a day. In cases of preparation for X-ray examination of the gastrointestinal tract, patients take 100 mg of the drug twice a day for three days before the examination.
The instructions to Ditsetel indicated that the drug may cause side effects from some body systems, namely:
- Abdominal pain, dysphagia, esophageal mucosal damage, diarrhea, nausea and vomiting (digestive system);
- Urticaria, rash, erythema and itching (skin).
Ditsetel can also cause allergic reactions.
Symptoms of drug overdose are diarrhea and flatulence. In such cases, the appointment of symptomatic therapy.
It is important to carefully follow the recommendations regarding the use of Ditsetel, as the drug may cause damage to the esophageal mucosa. In particular, such recommendations should be followed by patients with hernia of the esophageal opening and esophagitis.
With simultaneous use of the drug with anticholinergic agents, the relief of spasms may increase.
Drug synonyms are not released. The analogs of Ditsetel include Kellin, Avisan, Trigan, Librax, Spakovin, and Cistenal.
Terms and conditions of storage
In accordance with the instructions, Ditsetel should be stored in a well-ventilated, protected from light, dry and out of reach of children, at a temperature not exceeding 30 ºС.
From pharmacies, the drug is released on prescription. The shelf life of tablets, subject to the basic recommendations of the manufacturer, is five years.